Clinical pharmacokinetics of tyrosine kinase inhibitors: Focus on pyrimidines, pyridines and pyrroles

Clinical Pharmacokinetics

Volumn 50, Issue 9, 2011, Pages 551-603

  Di Gion, Paola ^a   Kanefendt, Friederike ^b   Lindauer, Andreas ^b   Scheffler, Matthias ^a   Doroshyenko, Oxana ^a   Fuhr, Uwe ^a   Wolf, Jrgen ^a   Jaehde, Ulrich ^b  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

Antineoplastics; Cancer; Dasatinib; Imatinib; Metabolism; Nilotinib; Pazopanib; Pharmacokinetics; Pyridines; Pyrimidines; Pyrroles; Receptor protein tyrosine kinase antagonists; Sorafenib; Sunitinib.

Indexed keywords

DASATINIB; IMATINIB; NILOTINIB; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB;

AREA UNDER THE CURVE; ATYPICAL CHRONIC MYELOID LEUKEMIA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONCENTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; RADIOACTIVITY; REVIEW;

DRUG INTERACTIONS; FEMALE; HUMANS; MALE; PROTEIN KINASE INHIBITORS; PYRIDINES; PYRIMIDINES; PYRROLES;

EID: 80051553376     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11593320-000000000-00000     Document Type: Review

References (292)

1. Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene 2000 Nov 20; 19 (49): 5548-57
2. Agrawal M, Garg RJ, Cortes J, et al. Tyrosine kinase inhibitors: the first decade. Curr Hematol Malig Rep 2010 Apr; 5 (2): 70-80
3. Lyseng-Williamson K, Jarvis B. Imatinib. Drugs 2001; 61 (12): 1765-74 (Pubitemid 32980506)
4. Snead JL,O'Hare T, Adrian LT, et al. Acute dasatinib exposure commits Bcr-Abl dependent cells to apoptosis. Blood 2009 Oct 15; 114 (16): 3459-63
5. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronicmyeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001 Apr 5; 344 (14): 1038-42 (Pubitemid 32267973)
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001 Apr 5; 344 (14): 1031-7 (Pubitemid 32267972)
7. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001 Apr 5; 344 (14): 1052-6 (Pubitemid 32267975)
8. Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 2002 Sep; 38 Suppl. 5: 77-82
9. An X, Tiwari AK, Sun Y, et al. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronicmyeloid leukemia: a review. Leuk Res 2010 Oct; 34 (10): 1255-68
10. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004 Mar 1; 22 (5): 935-42 (Pubitemid 41103606)
11. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos 2005 Oct; 33 (10): 1503-12 (Pubitemid 41323999)
12. Sedlacek HH. Kinase inhibitors in cancer therapy: a look ahead. Drugs 2000 Mar; 59 (3): 435-76 (Pubitemid 30213854)
13. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002 Aug 29; 418 (6901): 934 (Pubitemid 34976022)
14. Dancey J, Sausville EA. Issues and progress with protein kinase inhibitors for cancer treatment. Nat Rev Drug Discov 2003 Apr; 2 (4): 296-313 (Pubitemid 37361688)
15. Roberts PJ,Der CJ. Targeting theRaf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007 May 14; 26 (22): 3291-310 (Pubitemid 46763022)
16. Tibes R, Trent J, Kurzrock R. Tyrosine kinase inhibitors and the dawn of molecular cancer therapeutics. Annu Rev Pharmacol Toxicol 2005; 45: 357-84 (Pubitemid 40261810)
17. Gleevec (imatinib mesylate) tablets for oral use: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/pro duct/pi/pdf/gleevec-tabs.pdf [Accessed 2011 Jun 28]
18. Keam SJ. Dasatinib. Biodrugs 2008; 22 (1): 59-69
19. Steinberg M. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronicmyelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. Clin Ther 2007 Nov; 29 (11): 2289-308
20. Sprycel-(dasatinib) tablet for oral use: US prescribing information [online]. Available from URL: http://packageinserts.bms.com/pi/pi-sprycel.pdf [Accessed 2011 Jun 28]
21. Mcfarland KL, Wetzstein GA. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control 2009 Apr; 16 (2): 132-40
22. Giles FJ, Abruzzese E, Rosti G, et al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. Leukemia 2010 Jul; 24 (7): 1299-301
23. Tasigna-(nilotinib) capsules: US prescribing information [online]. Available from URL: http://www.pharma.us.novartis.com/product/pi/pdf/tasigna. pdf [Accessed 2011 Jun 28]
24. Takahashi K, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009 Apr; 127 (4): 494-9
25. PodarK,Tonon G, SattlerM, et al. The small-moleculeVEGFreceptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. Proc Natl Acad Sci USA 2006 Dec 19; 103 (51): 19478-83
26. Hurwitz HI, Dowlati A, Saini S, et al. Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res 2009 Jun 15; 15 (12): 4220-7
27. Cowey CL, Sonpavde G, Hutson TE. New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib. Onco Targets Ther 2010 Oct 5; 3: 147-55
28. Votrient (pazopanib) tablets: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda-docs/label/2009/ 022465lbl.pdf [Accessed 2011 Jun 28]
29. Smith RA, Barbosa J, Blum CL, et al. Discovery of heterocyclic ureas as a new class of raf kinase inhibitors: identification of a second generation lead by a combinatorial chemistry approach. Bioorg Med Chem Lett 2001 Oct 22; 11 (20): 2775-8 (Pubitemid 32925314)
30. Lyons JF, Wilhelm S, Hibner B, et al. Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 2001 Sep; 8 (3): 219-25 (Pubitemid 32947644)
31. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004 Oct 1; 64 (19): 7099-109 (Pubitemid 39331023)
32. Wilhelm S, Carter C, LynchM, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006 Oct; 5 (10): 835-44 (Pubitemid 44480537)
33. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24; 359 (4): 378-90
34. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renalcell carcinoma. N Engl J Med 2007 Jan 11; 356 (2): 125-34 (Pubitemid 46089673)
35. Nexavar (sorafenib) tablets, oral: US prescribing information [online]. Available from URL: http://berlex.bayerhealthcare.com/html/products/pi/Nexavar- PI.pdf [Accessed 2011 Jun 28]
36. Rini BI. Sunitinib. Expert Opin Pharmacother 2007 Oct; 8 (14): 2359-69 (Pubitemid 350001595)
37. Sablin MP, Dreyer C, Colichi C, et al. Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development. Expert Opin Drug Metab Toxicol 2010 Aug; 6 (8): 1005-15
38. Wildiers H, Fontaine C, Vuylsteke P, et al. Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer. Breast Cancer Res Treat 2010 Sep; 123 (2): 463-9
39. Mendel DB, Laird AD, Xin X, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003 Jan; 9: 327-37 (Pubitemid 36109749)
40. Chow LQM, Eckhardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol 2007 Mar 1; 25 (7): 884-96 (Pubitemid 350002890)
41. Sutent-(sunitinib malate) capsules: US prescribing information [online]. Available from URL: http://labeling.pfizer.com/ShowLabeling.aspx?id= 607 [Accessed 2011 Jun 28]
42. Shayani S. Dasatinib, a multikinase inhibitor: therapy, safety, and appropriate management of adverse events. Ther Drug Monit 2010 Dec; 32 (6): 680-7
43. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6- methylphenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4- ylami no)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004 Dec 30; 47 (27): 6658-61 (Pubitemid 40053752)
44. Thomas J,Wang L, Clark RE, et al. Active transport of imatinib into and out of cells: implications for drug resistance. Blood 2004Dec 1; 104 (12): 3739-45 (Pubitemid 39564452)
45. Lee FY, Wen ML, Bhide R, et al. Dasatinib (BMS-354825) overcomes multiple mechanisms of imatinib resistance in chronic myeloid leukemia (CML) [abstract no. 1994]. Blood 2005; 106 (11): 1994
46. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinibresistant Abl kinase domain mutants. Cancer Res 2005 Jun 1; 65 (11): 4500-5 (Pubitemid 40740783)
47. Talpaz M, ShahNP, KantarjianH, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl JMed 2006 Jun 15; 354: 2531-41 (Pubitemid 43882349)
48. Brave M, Goodman V, Kaminskas E, et al. Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008 Jan 15; 14 (2): 352-9 (Pubitemid 351226100)
49. Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res 2005 Jul 1; 11 (13): 4941-7 (Pubitemid 41557215)
50. Bergsland EK. Vascular endothelial growth factor as a therapeutic target in cancer. Am J Health Syst Pharm 2004 Nov 1; 61 (21 Suppl. 5): 4-11
51. Parikh AA, Ellis LM. The vascular endothelial growth factor family and its receptors. Hematol Oncol Clin North Am 2004 Oct; 18 (5): 951-71 (Pubitemid 39335753)
52. Vaziri SA, Kim J, Ganapathi MK, et al. Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. Curr Oncol Rep 2010 Mar; 12 (2): 102-8
53. Sloan B, Scheinfeld NS. Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy. Curr Opin Investig Drugs 2008 Dec; 9: 1324-35
54. Gotink KJ, Verheul HMW. Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 2010 Mar; 13: 1-14
55. Wan PT, Baker SD, Zandvliet AS, et al. Mechanism of activation of the RAFERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004 Mar 19; 116 (6): 855-67 (Pubitemid 38410730)
56. Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006 Mar 1; 98 (5): 326-34 (Pubitemid 43338212)
57. DuensingA,HeinrichMC,Fletcher CD, et al. Biology of gastrointestinal stromal tumors: KIT mutations and beyond. Cancer Invest 2004; 22 (1): 106-16 (Pubitemid 38523964)
58. Faivre S, Demetri G, SargentW, et al.Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007 Sep; 6 (9): 734-45 (Pubitemid 47338181)
59. Gorre ME, Sawyers CL. Molecular mechanisms of resistance to STI571 in chronic myeloid leukemia. Curr Opin Hematol 2002 Jul; 9 (4): 303-7 (Pubitemid 34596874)
60. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010 Apr 12; 9: 75
61. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 2005; 44 (9): 879-94 (Pubitemid 41252840)
62. European Medicines Agency. Tasigna capsules: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000798/WC500034394.pdf [Accessed 2011 Jun 28]
63. Goodman VL, Rock EP, Dagher R, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res 2007 Mar 1; 13 (5): 1367-73 (Pubitemid 46450424)
64. De Bruijn P, Sleijfer S, Lam MH, et al. Bioanalytical method for the quantification of sunitinib and its n-desethyl metabolite SU12662 in human plasma by ultra performance liquid chromatography/tandem triple-quadrupole mass spectrometry. J Pharm Biomed Anal 2010 Mar 11; 51 (4): 934-41
65. Bakhtiar R, Lohne J, Ramos L, et al. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002 Mar 5; 768 (2): 325-40 (Pubitemid 34158868)
66. Parise RA, Ramanathan RK, Hayes MJ, et al. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2003 Jul 5; 791 (1-2): 39-44 (Pubitemid 36638736)
67. Widmer N, Beguin A, Rochat B, et al. Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci 2004 Apr 25; 803 (2): 285-92 (Pubitemid 38455451)
68. Le Coutre P, Kreuzer KA, Pursche S, et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004 Apr; 53 (4): 313-23 (Pubitemid 38392356)
69. Haouala A, Zanolari B, Rochat B, et al. Therapeutic drug monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009 Jul 15; 877 (22): 1982-96
70. Roche S, McMahon G, Clynes M, et al. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. J Chromatogr B Analyt Technol Biomed Life Sci 2009 Dec 1; 877 (31): 3982-90
71. De Francia S, D'Avolio A, De Martino F, et al. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009 Jun 15; 877 (18-19): 1721-6
72. Zhou L, Meng F, Yin O, et al. Nilotinib for imatinib-resistant or-intolerant chronic myeloid leukemia in chronic phase, accelerated phase, or blast crisis: a single-and multiple-dose, open-label pharmacokinetic study in Chinese patients. Clin Ther 2009 Jul; 31 (7): 1568-75
73. Parise RA, Egorin MJ, Christner SM, et al. A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. J Chromatogr B Analyt Technol Biomed Life Sci 2009 Jul 1; 877 (20-21): 1894-900
74. Kumar R, Knick VB, Rudolph SK, et al. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther 2007 Jul; 6 (7): 2012-21 (Pubitemid 47052491)
75. Zhao M, Rudek MA, He P, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 2007 Feb 1; 846 (1-2): 1-7 (Pubitemid 46149480)
76. Jain L, Gardner ER, Venitz J, et al. Development of a rapid and sensitive LCMS/MS assay for the determination of sorafenib in human plasma. J Pharm Biomed Anal 2008 Jan 22; 46 (2): 362-7
77. Jain L, Gardner ER, FiggWD, et al. Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction. Pharmacotherapy 2010 Jan; 30 (1): 52-6
78. Minami H, Kawada K, Ebi H, et al. Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors. Cancer Sci 2008 Jul; 99 (7): 1492-8 (Pubitemid 351761743)
79. Blanchet B, Billemont B, Cramard J, et al. Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice. J Pharm Biomed Anal 2009 May 1; 49 (4): 1109-14
80. Heinz WJ, Kahle K, Helle-Beyersdorf A, et al. High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer Chemother Pharmacol 2011 Jul; 68 (1): 239-45
81. Minkin P, ZhaoM, Chen ZY, et al. Quantification of sunitinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life 2008 Oct 15; 874 (1-2): 84-8
82. Faivre S, Delbaldo C, Vera K, et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 2006 Jan 1; 24 (1): 25-35 (Pubitemid 46630490)
83. Fiedler W, Serve H, Dohner H, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 2005 Feb 1; 105 (3): 986-93 (Pubitemid 40170865)
84. Bello CL, Sherman L, Zhou J, et al. Effect of food on the pharmacokinetics of sunitinib malate (SU11248), a multi-targeted receptor tyrosine kinase inhibitor: results from a phase I study in healthy subjects. Anticancer Drugs 2006 Mar; 17 (3): 353-8
85. Lindauer A, Di Gion P, Kanefendt F, et al. Pharmacokinetic/ pharmacodynamic modeling of biomarker response to sunitinib in healthy volunteers. Clin Pharmacol Ther 2010 May; 87 (5): 601-8
86. Etienne-Grimaldi MC, Renée N, Izzedine H, et al. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2009 Nov 1; 877 (29): 3757-61
87. Gschwind H, Pfaar U, Waldmeier F, et al. Metabolism and disposition of Gleevec-(STI571) in healthy volunteers [abstract]. Drug Metab Rev 2001; 33 (1): 217
88. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol 2004 Feb; 44 (2): 158-62 (Pubitemid 38114314)
89. Nikolova Z, Peng B, Hubert M, et al. Bioequivalence, safety, and tolerability of imatinib tablets compared with capsules. Cancer Chemother Pharmacol 2004 May; 53 (5): 433-8 (Pubitemid 38553666)
90. Sparano BA, Egorin MJ, Parise RA, et al. Effect of antacid on imatinib absorption. Cancer Chemother Pharmacol 2009 Feb; 63 (3): 525-8
91. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004 Feb; 53 (2): 102-6 (Pubitemid 38186987)
92. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004 Oct; 54 (4): 290-4 (Pubitemid 39304422)
93. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004 Oct; 76 (4): 323-9 (Pubitemid 39313122)
94. Smith P, Bullock JM, Booker BM, et al. The influence of St John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004 Nov; 24 (11): 1508-14 (Pubitemid 39426346)
95. Bornhä user M, Pursche S, Bonin M, et al. Elimination of imatinib mesylate and its metabolite N-desmethyl-imatinib. J Clin Oncol 2005 Jun 1; 23 (16): 3855-6; author reply 3857-8
96. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003 Feb; 9 (2): 625-32 (Pubitemid 36182594)
97. Boddy AV, Sludden J, Griffin MJ, et al. Pharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemia. Clin Cancer Res 2007 Jul 15; 13 (14): 4164-9 (Pubitemid 47105979)
98. Delbaldo C, Chatelut E, Re M, et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patientswith advanced gastrointestinal stromal tumors. Clin Cancer Res 2006 Oct 15; 12 (20 Pt 1): 6073-8 (Pubitemid 44703771)
99. Judson I, Ma P, Peng B, et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005 Apr; 55 (4): 379-86 (Pubitemid 40379262)
100. Schmidli H, Peng B, Riviere GJ, et al. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005 Jul; 60 (1): 35-44 (Pubitemid 40942779)
101. Widmer N, Decosterd LA, Csajka C, et al. Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein [published erratum appears in Br J Clin Pharmacol 2010 Aug; 70 (2): 316].
102. Br J Clin Pharmacol 2006 Jul; 62 (1): 97-112
103. Treiber G, Wex T, Schleyer E, et al. Imatinib for hepatocellular cancer: focus on pharmacokinetic/pharmacodynamic modelling and liver function. Cancer Lett 2008 Feb 18; 260 (1-2): 146-54
104. Eckel F, von DS, Mayr M, et al. Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. Oncology 2005; 69 (5): 363-71 (Pubitemid 41797912)
105. Van Erp N, Gelderblom H, van Glabbeke M, et al. Effect of cigarette smoking on imatinib in patients in the Soft Tissue and Bone Sarcoma Group of the EORTC. Clin Cancer Res 2008 Dec 15; 14 (24): 8308-13
106. Petain A, Kattygnarath D, Azard J, et al. Population pharmacokinetics and pharmacogenetics of imatinib in children and adults. Clin Cancer Res 2008 Nov 1; 14 (21): 7102-9
107. Menon-Andersen D, Mondick JT, Jayaraman B, et al. Population pharmacokinetics of imatinib mesylate and its metabolite in children and young adults. Cancer Chemother Pharmacol 2009 Jan; 63 (2): 229-38
108. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004 Nov 1; 104 (9): 2655-60 (Pubitemid 39434944)
109. Ramanathan RK, Egorin MJ, Takimoto CH, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ DysfunctionWorkingGroup. J Clin Oncol 2008 Feb 1; 26 (4): 563-9 (Pubitemid 351264349)
110. Gibbons J, Egorin MJ, Ramanathan RK, et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advancedmalignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ DysfunctionWorking Group. J Clin Oncol 2008 Feb 1; 26 (4): 570-6 (Pubitemid 351264350)
111. Van Erp NP, Oostendorp RL, Guchelaar HJ, et al. Is rectal administration an alternative route for imatinib? Cancer Chemother Pharmacol 2007 Sep; 60 (4): 623-4 (Pubitemid 47084268)
112. Beumer JH, Natale JJ, Lagattuta TF, et al. Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. Pharmacotherapy 2006 Jul; 26 (7): 903-7
113. Burger H, Nooter K. Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib. Cell Cycle 2004 Dec; 3 (12): 1502-5 (Pubitemid 40521401)
114. Cusatis G, Sparreboom A. Pharmacogenomic importance of ABCG2. Pharmacogenomics 2008 Aug; 9 (8): 1005-9
115. Christopher LJ, Cui D, Wu C, et al. Metabolism and disposition of dasatinib after oral administration to humans. DrugMetab Dispos 2008 Jul; 36: 1357-64 (Pubitemid 351929320)
116. Eley T, Luc FR, Agrawal S, et al. Phase I study of the effect of gastric acid pH modulators of oral dasatinib in healthy subjects. J Clin Pharmacol 2009 Jun; 49: 700-9
117. Kim DW, Goh YT, Hsiao HH, et al. Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia. Int J Hematol 2009 Jun; 89: 664-72
118. Demetri GD, Lo Russo P, MacPherson IR, et al. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 2009 Oct 1; 15 (19): 6232-40
119. Kamath AV, Wang J, Lee FY, et al. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 2008 Mar; 61 (3): 365-76 (Pubitemid 350275972)
120. Luo FR, Yang Z, Camuso A, et al. Dasatinib (BMS-354825) pharmacokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 2006 Dec 1; 12 (23): 7180-6 (Pubitemid 44974520)
121. Dai H, Marbach P, Lemaire M, et al. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther 2003 Mar; 304 (3): 1085-92 (Pubitemid 36254421)
122. DemetriGD, Casali PG, Blay JY, et al. A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Clin Cancer Res 2009 Sep 15; 15 (18): 5910-6
123. Tojo A, Usuki K, Urabe A, et al. A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph+ CML or relapsed/refractory Ph+ ALL. Int J Hematol 2009 Jun; 89 (5): 679-88
124. Yin OQ, Gallagher N, Li A, et al. Effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2010 Feb; 50 (2): 188-94
125. TanakaC,Yin OQ, Smith T, et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011 Jan; 51 (1): 75-83
126. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006 Jun 15; 354: 2524-51
127. Tanaka C, Smith T, Kantarjian H, et al. Clinical pharmacokinetics (PK) of AMN107, a novel inhibitor of Bcr-Abl, in healthy subjects and patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) or relapsed/refractory Ph+ acute lymphocytic leukemia (Ph+ ALL) [abstract no. 3095]. J Clin Oncol 2006; 24 (18 Suppl.): 3095
128. Kagan M, Tran P, Fischer V, et al. Safety, pharmacokinetics (PK), metabolism, and mass balance of 14C-AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl tyrosine kinase, in healthy subjects [abstract no. 4887]. Blood 2005; 106 (11): 4887
129. Trent J, MolimardM. Pharmacokinetics and pharmacodynamics of nilotinib in gastrointestinal stromal tumors. Semin Oncol 2011 Apr; 38 Suppl. 1: 28-33
130. Tanaka C, Yin OQ, Sethuraman V, et al. Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib. Clin Pharmacol Ther 2010 Feb; 87 (2): 197-203
131. HazarikaM, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008 Sep 1; 14 (17): 5325-31
132. Kim KP, Ryu MH, Yoo C, et al. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability. Cancer Chemother Pharmacol. Epub 2010 Oct 19
133. Deininger MW. Nilotinib. Clin Cancer Res 2008 Jul 1; 14 (13): 4027-31
134. GlaxoSmithKline. An open-label, two-part study to characterize the pharmacokinetics of a single intravenous dose of pazopanib (GW786034) and the absorption, distribution, metabolism and elimination of a single oral [14C] labeled dose of pazopanib in subjects with solid tumor malignancies [study no. VEG10004; online]. Available from URL: http://download.gskclinicalstudyregister. com/files/21149.pdf [Accessed 2011 Jun 28]
135. Heath EI, Chiorean EG, Sweeney CJ, et al. A phase I study of the
136. Shibata SLJ, Chung VM, Lenz H, et al. A phase I and pharmacokinetic single agent study of pazopanib in patients with advanced malignancies and varying degrees of liver dysfunction [abstract no. 2571]. JClin Oncol 2010; 28 (Suppl.): 15S
137. Lang JM, Harrison MR. Pazopanib for the treatment of patients with advanced renal cell carcinoma. Clin Med Insights Oncol 2010 Oct 1; 4: 95-105
138. GlaxoSmithKline. Votrient-tablets: Australian product information [online]. Available from URL: http://gsk.com.au/resources.ashx/prescription medicinesproductschilddataproinfo/989/FileName/77D7CF3E1F4D30BF6D0 45C51F6F34C95/Votrient-PI-(Clean).pdf [Accessed 2011 Jun 28]
139. GlaxoSmithKline. An open-label, two-period, randomized, crossover study, to evaluate the effect of food on the pharmacokinetics of single doses of pazopanib in cancer patients [study no. VEG10005; online]. Available from URL: http://download.gsk-clinicalstudyregister.com/files/21150.pdf [Accessed 2011 Jun 28]
140. Strumberg D, Richly H, Hilger RA, et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005 Feb 10; 23 (5): 965-72 (Pubitemid 46202316)
141. Awada A, Hendlisz A, Gil T, et al. Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours. Br J Cancer 2005 May 23; 92 (10): 1855-61 (Pubitemid 40826133)
142. Clark JW, Eder JP, Ryan D, et al. Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res 2005 Aug 1; 11 (15): 5472-80 (Pubitemid 41060823)
143. Moore M, Hirte HW, Siu L, et al. Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors. Ann Oncol 2005 Oct; 16 (10): 1688-94 (Pubitemid 41510145)
144. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Sep 10; 24 (26): 4293-300 (Pubitemid 46630787)
145. Furuse J, Ishii H, Nakachi K, et al. Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 2008 Jan; 99 (1): 159-65 (Pubitemid 350239045)
146. Miller AA, Murry DJ, Owzar K, et al. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 2009 Apr 10; 27 (11): 1800-5
147. Lathia C, Lettieri J, Cihon F, et al. Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics. Cancer Chemother Pharmacol 2006 May; 57 (5): 685-92
148. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009 Oct 1; 15 (19): 6062-9
149. Gnoth MJ, Sandmann S, Engel K, et al. In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein. Drug Metab Dispos 2010 Aug; 38 (8): 1341-6
150. Kane RC, Farrell AT, Saber H, et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 2006 Dec 15; 12 (24): 7271-8 (Pubitemid 46095398)
151. Washington C, Eli M, Bello C. The effect of ketoconazole (KETO), a potent CYP 3A4 inhibitor, on SU011248 pharmacokinetics (PK) in Caucasian and Asian healthy subjects [abstract no. 553]. 39th Annual Meeting, American Society of Clinical Oncology; 2003 May 31-Jun 3; Chicago (IL)
152. Britten CD, Kabbinavar F, Randolph HJ, et al. A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. Cancer Chemother Pharmacol 2008 Mar; 61 (3): 515-24 (Pubitemid 350275988)
153. Bello C, Toh M, Garrett M, et al. Pharmacokinetics of sunitinib in patients with severe renal impairment or end stage renal disease on hemodialysis [abstract no. 162]. 33rd Conference of the European Society for Medical Oncology; 2008 Sep 12-16; Stockholm
154. Bello CL, Garrett M, Sherman L, et al. Pharmacokinetics of sunitinib malate in subjects with hepatic impairment. Cancer Chemother Pharmacol 2010 Sep; 66 (4): 699-707
155. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer 2009 Jul; 45 (11): 1959-68
156. Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol 2010Mar; 65 (4): 649-60
157. European Medicines Agency. Sutent capsules: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000687/WC500057737.pdf [Accessed 2011 Jun 28]
158. Haznedar J, Patyna S, Bello C, et al. Single-and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemother Pharmacol 2009 Sep; 64 (4): 691-706
159. O'Farrell AM, Foran JM, FiedlerW, et al. An innovative phase I clinical study demonstrates inhibition ofFLT3 phosphorylation by SU11248 in acutemyeloid leukemia patients. Clin Cancer Res 2003 Nov 15; 9 (15): 5465-76
160. Burstein HJ, Elias AD, Rugo HS, et al. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2008 Apr 10; 26 (11): 1810-6
161. Bornhä user M, Jenke A, Freiberg-Richter J, et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its Ndesmethylated metabolite in cerebral spinal fluid. Ann Hematol 2004 Jun; 83: 401-2 (Pubitemid 38684457)
162. Breedveld P, Pluim D, Cipriani G, et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinibmesylate (Gleevec): implications for the use of breast cancer resistance protein and Pglycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res 2005 Apr 1; 65 (7): 2577-82 (Pubitemid 40490054)
163. Kilic T, Alberta JA, Zdunek PR, et al. Intracranial inhibition of plateletderived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class. Cancer Res 2000 Sep 15; 60 (18): 5143-50
164. TakayamaN, Sato N, O'Brien SG, et al. Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid. Br J Haematol 2002 Oct; 119: 106-8 (Pubitemid 35176504)
165. Patel S, Zalcberg JR. Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer 2008 Mar; 44 (4): 501-9
166. Kretz O, Weiss HM, Schumacher MM, et al. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2004 Aug; 58 (2): 212-6 (Pubitemid 39044003)
167. Gambacorti-Passerini CB, Tornaghi L, Marangon E, et al. Imatinib concentrations in human milk. Blood 2007 Feb 15; 109 (4): 1790 (Pubitemid 46239616)
168. Russell MA, Carpenter MW, Akhtar MS, et al. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol 2007 Apr; 27 (4): 241-3 (Pubitemid 46487717)
169. Ali R, Ozkalemkas F, Kimya Y, et al. Imatinib use during pregnancy and breast feeding: a case report and review of the literature. Arch Gynecol Obstet 2009 Aug; 280 (2): 169-75
170. European Medicines Agency. Sprycel tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en- GB/document-library/EPAR-Product-Information/human/000709/WC500056998.pdf [Accessed 2011 Jun 28]
171. Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood 2008 Aug 15; 112 (4): 1005-12
172. Chen Y, Agarwal S, Shaik NM, et al. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib. J Pharmacol Exp Ther 2009 Sep; 330 (3): 956-63
173. Iwamoto FM, Lamborn KR, Robins HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol 2010 Aug; 12 (8): 855-61
174. Jain L, Woo S, Gardner ER, et al. Population pharmacokinetic analysis of sorafenib in patients with solid tumors. Br J Clin Pharmacol 2011 Aug; 72 (2): 294-305
175. Lagas JS, van Waterschoot RA, Sparidans RW, et al. Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.Mol Cancer Ther 2010 Feb; 9 (2): 319-26
176. Tang SC, Lagas JS, Lankheet NA, et al. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int J Cancer. Epub 2011 Feb 23
177. Sherman L, Peng G, Patyna S, et al. Open-label, single-dose, phase I study evaluating the mass balance and pharmacokinetics (PKs) of sunitinib (SU) in healthy male subjects [abstract no. 731]. 14th European Cancer Conference; 2007 Sep 23-27; Barcelona
178. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev 1988 Mar; 40 (1): 1-47
179. Fournier T, Medjoubi NN, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000 Oct 18; 1482 (1-2): 157-71
180. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev 2001 May; 33 (2): 161-235 (Pubitemid 32703255)
181. Rochat B, Fayet A, Widmer N, et al. Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry. J Mass Spectrom 2008 Jun; 43 (6): 736-52 (Pubitemid 351954808)
182. Van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 2007 Dec 15; 13 (24): 7394-400
183. Nebot N, Crettol S, d'Esposito F, et al. Participation of CYP2C8 and CYP3A4 in the N-demethylation of imatinib in human hepatic microsomes. Br J Pharmacol 2010 Nov; 161 (5): 1059-69
184. Rochat B, Zoete V, Grosdidier A, et al. In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1. Biopharm Drug Dispos 2008 Mar; 29 (2): 103-18 (Pubitemid 351516391)
185. Gréen H, Skoglund K, Rommel F, et al. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010 Apr; 66 (4): 383-6
186. Cashman JR. Human flavin-containing monooxygenase: substrate specificity and role in drug metabolism. Curr Drug Metab 2000 Sep; 1 (2): 181-91
187. Zhou SF, Wang B, Yang LP, et al. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metab Rev 2010 May; 42 (2): 268-354
188. Gurney H, Wong M, Balleine RL, et al. Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype. Clin Pharmacol Ther 2007 Jul; 82 (1): 33-40 (Pubitemid 46944197)
189. Wang Y, Zhou L, Dutreix C, et al. Effects of imatinib (Glivec) on the pharmacokinetics of metoprolol, a CYP2D6 substrate, in Chinese patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2008 Jun; 65 (6): 885-92 (Pubitemid 351677440)
190. Gora-Tybor J, Robak T. Targeted drugs in chronic myeloid leukaemia. Curr Med Chem 2008; 15 (29): 3036-51
191. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008 Nov; 30 (11): 1956-75
192. Dejonge MSS, Verweij J, Collins TS, et al. A phase I, open-label study of the safety and pharmacokinetics of pazopanib and lapatinib administered concurrently [abstract no. 3088]. J Clin Oncol 2006; 24 (Suppl.): 142S
193. Meza-Junco J, Chu QS, Christensen O, et al. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 2009 Dec; 65 (1): 1-4
194. Houk BE, Bello CL, Kang D, et al. A population pharmacokinetic metaanalysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res 2009 Apr 1; 15 (7): 2497-506
195. Takahashi N,Miura M. Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase. Pharmacology 2011 Apr 6; 87 (5-6): 241-8
196. Ramalingam S, Lagattuta TF, Egorin MJ, et al. Biliary excretion of imatinib mesylate and its metabolite CGP 74588 in humans. Pharmacotherapy 2004 Sep; 24 (9): 1232-5 (Pubitemid 39128848)
197. Takahashi N, Miura M, Scott SA, et al. Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia. J Hum Genet 2010 Nov; 55 (11): 731-7
198. Dagher R, Cohen M, WilliamsG, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectablemalignant gastrointestinal stromal tumors. Clin Cancer Res 2002 Oct; 8 (10): 3034-8 (Pubitemid 35155011)
199. Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children's Oncology Group Phase I Consortium. J Clin Oncol 2011 Mar 1; 29 (7): 839-44
200. Dubois SG, Shusterman S, Ingle AM, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a Children's Oncology Group study. Clin Cancer Res. Epub 2011 Jun 20
201. Desar IM, Burger DM, Van Hoesel QG, et al. Pharmacokinetics of sunitinib in an obese patient with a GIST. Ann Oncol 2009 Mar; 20 (3): 599-600
202. Shirao K, Nishida T, Doi T, et al. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate. Invest New Drugs 2010 Dec; 28 (6): 866-75
203. Yin OQ, Gallagher N, Tanaka C, et al. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study. Clin Ther 2009; 31 (Pt 2): 2459-69
204. Keisner SV, Shah SR. Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 2011 Mar 5; 71 (4): 443-54
205. Franke RM, SparreboomA. Inhibition of imatinib transport by uremic toxins during renal failure. J Clin Oncol 2008 Sep 1; 26 (25): 4226-7
206. Judson IR. Imatinib for patients with liver or kidney dysfunction: no need to modify the dose. J Clin Oncol 2008 Feb 1; 26 (4): 521-2 (Pubitemid 351264343)
207. Kennoki T, Kondo T, Kimata N, et al. Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center. Jpn J Clin Oncol 2011 May; 41 (5): 647-55
208. Hilger RA, Richly H, Grubert M, et al. Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis. Int J Clin Pharmacol Ther 2009 Jan; 47 (1): 61-4
209. Ferraris E, Di Cesare P, Lasagna A, et al. Use of sorafenib in two metastatic renal cell cancer patients with end-stage renal impairment undergoing replacement hemodialysis. Tumori 2009 Jul-Aug; 95 (4): 542-4
210. Shinsako K, Mizuno T, Terada T, et al. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol 2010 Oct; 15 (5): 512-4
211. Adams VR, Leggas M. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors. Clin Ther 2007 Jul; 29 (7): 1338-53 (Pubitemid 47348120)
212. Khosravan R, Toh M, Garrett M, et al. Pharmacokinetics and safety of sunitinib malate in subjects with impaired renal function. J Clin Pharmacol 2010 Apr; 50 (4): 472-81
213. Izzedine H, Etienne-Grimaldi MC, Renée N, et al. Pharmacokinetics of sunitinib in hemodialysis. Ann Oncol 2009 Jan; 20 (1): 190-2
214. Lainakis G, Bamias A, Psimenou E, et al. Sunitinib treatment in patients with severe renal function impairment: a report of four cases by the Hellenic Cooperative Oncology Group. Clin Nephrol 2009 Jul; 72 (1): 73-8
215. Park S, Lee J, Park SH, et al. Treatment of hemodialyzed patients with sunitinib in renal cell carcinoma. Chemotherapy 2010; 56 (6): 485-91
216. Leblond FA, Giroux L, Villeneuve JP, et al. Decreased in vivo metabolism of drugs in chronic renal failure. Drug Metab Dispos 2000 Nov; 28 (11): 1317-20
217. Dowling TC, Briglia AE, Fink JC, et al. Characterization of hepatic cytochrome p4503A activity in patients with end-stage renal disease. Clin Pharmacol Ther 2003 May; 73 (5): 427-34 (Pubitemid 36549827)
218. Michaud J, Nolin TD, Naud J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008 Oct; 108 (2): 157-63
219. Egorin MJ, Shah DD, Christner SM, et al. Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. Br J Clin Pharmacol 2009 Sep; 68 (3): 370-4
220. Shukla S, Sauna ZE, Ambudkar SV. Evidence for the interaction of imatinib at the transport-substrate site(s) of the multidrug-resistance-linked ABC drug transporters ABCB1 (P-glycoprotein) and ABCG2. Leukemia 2008 Feb; 22 (2): 445-7 (Pubitemid 351250557)
221. Shen T, Kuang YH, Ashby CR, et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS One 2009 Oct 20; 4 (10): e7520
222. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004 Mar; 18 (3): 401-8 (Pubitemid 38425851)
223. White DL, Saunders VA, Quinn SR, et al. Imatinib increases the intracellular concentration of nilotinib, which may explain the observed synergy between these drugs. Blood 2007 Apr 15; 109 (8): 3609-10 (Pubitemid 46572560)
224. Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002 May; 8 (5): 935-42 (Pubitemid 34520420)
225. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol 2008 Jun; 10 (3): 330-40
226. Bilgi N, Bell K, Ananthakrishnan AN, et al. Imatinib and Panax ginseng: a potential interaction resulting in liver toxicity. Ann Pharmacother 2010 May; 44 (5): 926-8
227. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003 Nov 17; 89 (10): 1855-9 (Pubitemid 37533259)
228. Watkins PB. The role of cytochromes P-450 in cyclosporinemetabolism. JAm Acad Dermatol 1990 Dec; 23: 301-11
229. Connolly RM, Rudek MA, Garrett-Mayer E, et al. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer. Breast Cancer Res Treat 2011 May; 127 (1): 153-62
230. Kim DW, Tan EY, Jin Y, et al. Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia. Br J Clin Pharmacol 2011 Feb; 71 (2): 199-206
231. Hegedus C, Ozvegy-Laczka C, Apá ti A, et al. Interactions of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties. Br J Pharmacol 2009 Oct; 158 (4): 1153-64
232. Eley T, Varga D, Sanil A, et al. The effects of rifampin on the pharmacokinetics of dasatinib and two metabolites in healthy subjects. AAPS J 2006; 8 (Suppl. 2) [online]. Available from URL: http://www.aapsj.org/abstracts/ AM-2006/AAPS2006-003076.pdf [Accessed 2011 Jul 7]
233. Johnson FM, Agrawal S, Burris H, et al. Phase 1 pharmacokinetic and druginteraction study of dasatinib in patients with advanced solid tumors. Cancer 2010 Mar 15; 116 (6): 1582-91
234. Singer JB, Shou Y, Giles F, et al. UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia. Leukemia 2007 Nov; 21 (11): 2311-5 (Pubitemid 350019230)
235. Fujita K, Sugiyama M, Akiyama Y, et al. The small-molecule tyrosine kinase inhibitor nilotinib is a potent noncompetitive inhibitor of the SN-38 glucuronidation by human UGT1A1. Cancer Chemother Pharmacol 2011 Jan; 67 (1): 237-41
236. Tiwari AK, SodaniK,Wang SR, et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009 Jul 15; 78 (2): 153-61
237. Yin OQ, Gallagher N, Fischer D, et al. Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib. J Clin Pharmacol 2010 Aug; 50 (8): 960-7
238. YinOQ,GallagherN, FischerD, et al. Effects of nilotinib on single-dose warfarin pharmacokinetics and pharmacodynamics: a randomized, single-blind, twoperiod crossover study in healthy subjects. Clin Drug Investig 2011; 31 (3): 169-79
239. Goh BC, Reddy NJ, Dandamudi U, et al. An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified Cooperstown 5+1 cocktail in patients with advanced solid tumors. Clin Pharmacol Ther 2010 Nov; 88 (5): 652-9
240. GlaxoSmithKline. An open-label, two-period, fixed-sequence study in healthy volunteers to evaluate the effects of repeat oral dosing of ketoconazole on the pharmacokinetics of a single dose of pazopanib (GW786034) administered as eye drops [study no. MD7110861; online]. Available from URL: http://down load.gsk-clinicalstudyregister.com/files/20890.pdf [Accessed 2011 Jun 28]
241. GlaxoSmithKline. An open-label, safety, pharmacokinetic and pharmacodynamic study of multiple doses of GW786034 and lapatinib concomitantly administered in cancer patients [study no. VEG10006; online]. Available from URL: http://download.gsk-clinicalstudyregister.com/files/21151.pdf [Accessed 2011 Jun 28]
242. Tan AR, Dowlati A, Jones SF, et al. Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors. J Clin Oncol 2010; 15 (12): 1253-61
243. Flaherty KT, Lathia C, Frye RF, et al. Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. Epub 2011 Feb 25
244. Reardon DA, Vredenburgh JJ, Desjardins A, et al. Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma. JNeurooncol 2011 Jan; 101 (1): 57-66
245. Vaishampayan UN, Burger AM, Sausville EA, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res 2010 Jul 15; 16 (14): 3795-804
246. Gomo C, Coriat R, Faivre L, et al. Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. Epub 2010 Aug 13
247. Duran I, Hotté SJ, Hirte H, et al. Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 2007 Aug 15; 13 (16): 4849-57 (Pubitemid 47294792)
248. Quintela-Fandino M, Le Tourneau C, Duran I, et al. Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort. Mol Cancer Ther 2010 Mar; 9 (3): 751-60
249. Adjei AA, Molina JR, Mandrekar SJ, et al. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clin Cancer Res 2007 Mar 1; 13 (9): 2684-91 (Pubitemid 46788036)
250. Flaherty KT, Schiller J, Schuchter LM, et al. A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel. Clin Cancer Res 2008 Aug 1; 14 (15): 4836-42
251. Mross K, Steinbild S, Baas F, et al. Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors. Int J Clin Pharmacol Ther 2003 Dec; 41 (12): 618-9
252. European Medicines Agency. Nexavar (sorafenib) 200 mg film-coated tablets: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Inf ormation/human/000690/WC500027704.pdf [Accessed 2011 Jun 28]
253. Richly H, Henning BF, Kupsch P, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors. Ann Oncol 2006 May; 17 (5): 866-73
254. Brendel E, Ludwig M, Lathia C, et al. Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2011 Jul; 68 (1): 53-61
255. Escudier B, Lassau N, Angevin E, et al. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma. Clin Cancer Res 2007 Mar 15; 13 (6): 1801-9 (Pubitemid 46952949)
256. Niwakawa M, Hashine K, Yamaguchi R, et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma. Invest New Drugs. Epub 2011 Jan 19
257. Kupsch P, Henning BF, Passarge K, et al. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin Colorectal Cancer 2005 Sep; 5 (3): 188-96
258. Siu LL, Awada A, Takimoto CH, et al. Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer. Clin Cancer Res 2006 Jan 1; 12 (1): 144-51 (Pubitemid 43166188)
259. Infante JR, Jones SF, Bendell JC, et al. A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine. Cancer Chemother Pharmacol. Epub 2011 May 28
260. Awada A, Gil T,Whenham N, et al. Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial. J Clin Pharmacol. Epub 2011 Jan 5
261. Desar IM, Timmer-Bonte JN, BurgerDM, et al. A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patientswith advanced solid cancer. Br JCancer 2010Nov 23; 103 (11): 1637-43
262. Bello C, Houk B, Sherman L, et al. The effect of rifampin on the pharmacokinetics of sunitinib malate (SU11248) in Caucasian and Japanese populations [abstract no. 430]. 13th European Cancer Conference; 2005 Oct 30-Nov 3; Paris
263. Hamberg P, Steeghs N, LoosWJ, et al. Decreased exposure to sunitinib due to concomitant administration of ifosfamide: results of a phase I and pharmacokinetic study on the combination of sunitiniband ifosfamide in patients with advanced solid malignancies. Br JCancer 2010 Jun 8; 102 (12): 1699-706
264. Van Erp NP, Baker SD, Zandvliet AS, et al. Marginal increase of sunitinib exposure by grapefruit juice. Cancer Chemother Pharmacol 2011 Mar; 67 (3): 695-703
265. Motzer RJ, Hudes GR, Ginsberg MS, et al. Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma. Am J Clin Oncol 2010 Dec; 33 (6): 614-8
266. Kozloff M, Chuang E, Starr A, et al. An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol 2010 Jul; 21 (7): 1436-41
267. Heath EI, Blumenschein Jr GR, Cohen RB, et al. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol. Epub 2010 Dec 8
268. Robert F, Sandler A, Schiller JH, et al. Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemother Pharmacol 2010 Sep; 66 (4): 669-80
269. de Jonge MJ, Dumez H, Kitzen JJ, et al. Phase I safety and pharmacokinetic study of SU-014813 in combination with docetaxel in patients with advanced solid tumours. Eur J Cancer 2011 Jun; 47 (9): 1328-35
270. Boven E, Massard C, Armand JP, et al. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer 2010 Sep 28; 103 (7): 993-1000
271. Reck M, Frickhofen N, Cedres S, et al. Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: a phase I dose-escalation study. Lung Cancer 2010 Nov; 70 (2): 180-7
272. Okamoto I, Shimizu T, Miyazaki M, et al. Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors. Invest New Drugs. Epub 2010 Oct 20
273. Sweeney CJ, Chiorean EG, Verschraegen CF, et al. A phase I study of sunitinib plus capecitabine in patients with advanced solid tumors. J Clin Oncol 2010 Oct 10; 28 (29): 4513-20
274. Cornely OA, Böhme A, Buchheidt D, et al. Primary prophylaxis of invasive fungal infections in patients with hematologic malignancies: recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Haematologica 2009 Jan; 94 (1): 113-22
275. Rochat B. Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolism. Clin Pharmacokinet 2005; 44 (4): 349-66 (Pubitemid 40663682)
276. Hu S, Franke RM, Filipski KK, et al. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 2008 May 15; 14: 3141-8
277. Eechoute K, Franke RM, Loos WJ, et al. Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther 2011 Jun; 89 (6): 816-20
278. Gardner ER, Burger H, van Schaik RH, et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 2006 Aug; 80 (2): 192-201 (Pubitemid 44160695)
279. Yamakawa Y, Hamada A, Shuto T, et al. Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia. Clin Pharmacol Ther 2011 Jul; 90 (1): 157-63
280. Yamakawa Y, Hamada A, Nakashima R, et al. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit 2011 Apr; 33 (2): 244-50
281. Dulucq S, Bouchet S, Turcq B, et al. Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2008 Sep 1; 112 (5): 2024-7
282. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clin Cancer
283. Xu CF, Reck BH, Xue Z, et al. Pazopanib-induced hyperbilirubinemia is associated with Gilbert's syndrome UGT1A1 polymorphism. Br J Cancer 2010 Apr 27; 102 (9): 1371-7
284. Van Erp NP, Eechoute K, van der Veldt AA, et al. Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity. J Clin Oncol 2009 Sep 10; 27 (26): 4406-12
285. Van der Veldt AA, Eechoute K, Gelderblom H, et al. Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib. Clin Cancer Res 2011 Feb 1; 17 (3): 620-9
286. Jabbour E, Cortes JE, Kantarjian HM. Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? Mayo Clin Proc 2009 Feb; 84 (2): 161-9
287. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007 Apr 15; 109 (8): 3496-9 (Pubitemid 46572540)
288. Sohn SK, Oh SJ, Kim BS, et al. Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. Leuk Lymphoma 2011 Jun; 52 (6): 1024-9
289. Von Mehren M, Widmer N. Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? Cancer Treat Rev 2011 Jun; 37 (4): 291-9
290. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronicmyelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011 Jul 15; 57 (1): 56-62
291. Condorelli F, Genazzani AA. Dasatinib: is it all in the dose? BioDrugs 2010 Jun; 24 (3): 157-63
292. Demetri GD, Heinrich MC, Fletcher JA, et al. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res 2009 Sep 15; 15 (18): 5902-9